
Effects of Grapefruit Juice on Intestinal P-glycoprotein
from Pharmacotherapy
Discussion
Our results indicate that grapefruit juice decreased the rate (ka, Tlag), but not the extent (AUC), of digoxin oral absorption in healthy volunteers. It did not affect systemic elimination of digoxin, as half-life and renal clearance were unchanged in the presence of juice. The decrease in the rate of digoxin absorption and lack of effect on AUC are not consistent with inhibition of intestinal P-gp by grapefruit juice. In fact, inhibition of P-gp-mediated intestinal drug efflux would be expected to increase the rate and extent of digoxin absorption, as reported with known P-gp inhibitors such as quinidine and other drugs.[29-31] Since intestinal P-gp plays an important role in oral digoxin absorption[8] and since the effects of grapefruit juice appear to be confined to the intestine,[15, 32] our results indicate that the juice does not significantly affect P-gp-mediated digoxin intestinal transport.
Similar to our findings, in vitro data show that grapefruit juice, at a concentration of 5% of normal strength, does not affect efflux of the P-gp substrates digoxin or vinblastine.[20] Other in vitro results indicate grapefruit juice constituents may inhibit P-gp.[33] In contrast to these data, it was suggested that grapefruit juice activates P-gp,[22] although that was later attributed to equipment-related artifact.[34] Thus, at the concentrations studied, the juice does not affect in vitro drug transport by P-gp, although applicability of these results to drug interactions in humans is uncertain, since only low juice concentrations can be reliably evaluated in these polarized cell lines. Consequently, in vivo studies are required to characterize any clinical effect of grapefruit juice on P-gp function.
The effect of a single serving of grapefruit juice administered 30 minutes before oral digoxin was evaluated in healthy volunteers in the only other report describing the juice's effect on digoxin disposition.[21] In contrast to our results, grape-fruit juice resulted in slight increases in Cmax, AUC0-4, and AUC0-24; however, it did not change AUC0-48 and renal clearance, in agreement with our findings. The minor differences in the effects of juice early after digoxin administration could be due to differences in the duration and quantity of pretreatment juice (single dose vs 3 times/day for 5 days in our study), variability in active constituents in grapefruit juice products, digoxin tablet formulation (French product vs Lanoxin), or other dietary or environmental factors (dietary salt[35]) that may affect activity and/or expression of intestinal drug transporters. Despite these minor differences in early digoxin absorption, neither study found significant changes in longer-term exposure (>/= AUC0-48) to digoxin when administered with the juice. Collectively, these results indicate that neither short- nor long-term grapefruit juice ingestion has a significant effect on intestinal P-gp activity, and that inhibition of P-gp does not play an important role in drug interactions involving grapefruit juice.
Although the overall results of these two studies indicate that, on average, grapefruit juice has little effect on digoxin oral bioavailability, it led to significant interindividual variability in indexes characterizing digoxin absorption (Cmax and AUC0-4) in our study. Even though the juice's mean effect on digoxin oral availability was small and not likely clinically significant, the large variation in response suggests that in some individuals this interaction could be of clinical significance. Although the variability in the effects of juice could be due to random variation in a small number of subjects, the strong inverse correlation between water-phase digoxin Cmax and AUC0-4 and extent of decrease in each parameter indicates that subjects with the highest net drug uptake during the control phase had the greatest reduction in absorption when given juice. Since intestinal P-gp plays an important role in digoxin absorption,[8] our results suggest that one source of variability in response to grapefruit juice may be related to the level of P-gp activity in the intestine. However, this reduction in digoxin absorption in subjects with high baseline net drug uptake would not be consistent with juice-mediated inhibition of intestinal P-gp, in which availability would be expected to increase. Although our observed individual variability may be due to random variation in a small group of subjects, it is interesting to speculate on other potential sources of this variability in response to grapefruit juice.
Studies characterizing drug uptake transport by organic anion transporting polypeptide (OATP) may provide additional insight into interindividual responses to grapefruit juice. The OATPs are a family of drug uptake transporters expressed in many of the same organs as P-gp, including liver, kidneys, brain, and intestine.[36-39] The two putative pure P-gp substrates, digoxin and fexofenadine, both also appear to be transported by OATP, and considerable overlap is reported in drugs that are inhibitors or substrates for both P-gp and OATP.[36, 37, 40] Grapefruit, orange, and apple juices inhibit OATP-mediated in vitro transport of fexofenadine.[20] Consistent with in vitro findings, these juices also significantly reduced the rate (Cmax) and extent (AUC) of fexofenadine absorption in healthy volunteers, presumably by inhibiting intestinal drug uptake by OATP.[20, 41] It should be noted, however, that specific intestinal uptake transporters for either digoxin or fexofenadine have yet to be identified. Similar to our digoxin data, the juice-mediated decrease in fexofenadine AUC was greatest in subjects with the highest AUC during the water phase of the study.[20] Thus, grapefruit juice reduced absorption of each agent in subjects with the highest net drug uptake during the control phase. These data suggest that, for drugs that are substrates for both P-gp and OATP, relative contributions of intestinal drug efflux (P-gp) and drug uptake (OATP) may be important determinants of net drug absorption, as well as an individual's response to grapefruit juice. If grapefruit juice inhibits OATP but not P-gp,[20] it would be expected to produce its greatest effect on drug absorption when intestinal drug uptake by OATP is high relative to P-gp-mediated efflux. Our results with digoxin, as well as those of others with fexofenadine,[20] of an inverse relationship between drug absorption during the control phase and the effect of grapefruit juice support this concept. Moreover, our findings of a grapefruit juice-mediated delay in digoxin absorption is also consistent with inhibition of uptake rather than efflux transport.
If the effect of grapefruit juice depends on the net balance of drug uptake and efflux transport, recently identified single-nucleotide polymor-phisms (SNPs) in the MDR1 gene that are associated with alterations in intestinal P-gp expression[42, 43] and substrate drug pharmaco-kinetics[42, 44-47] could affect the relative balance of intestinal drug uptake and efflux. Although several MDR1 SNPs have been identified,[44] the exon 26 C3435T polymorphism is the best characterized SNP associated with alterations in P-gp expression and activity. Individuals homozygous for 3435T had high concentrations of intestinal MDR1 mRNA.[43] Consistent with this finding, reduced absorption of digoxin and fexofenadine is also reported in individuals with the TT genotype.[44, 45, 47] In contrast, Caucasian subjects with the TT genotype had lower intestinal P-gp levels and increased digoxin plasma concentrations compared with wild-type homozygotes.[42] Since the C3435T SNP is closely linked to one at exon 21 G2677T, the effect of C3435T and G2677T SNP on digoxin disposition was determined in healthy Japanese volunteers.[46] Similar to the work of others,[42] higher bioavail-ability and decreased renal digoxin clearance were found in individuals homozygous mutant for the MDR1 SNPs compared with wild-type homozygotes. Finally, a study in German Caucasian subjects found no association between C3435T genotype and fexofenadine pharmaco-kinetics.[48]
Our results suggesting an association between digoxin disposition and C3435T genotype are in agreement with those of others suggesting reduced P-gp activity in CC subjects.[44, 45, 47] We observed trends toward higher AUC, Cmax, and ka during the water phase in these subjects compared with those carrying a T allele. After grapefruit juice administration, digoxin AUC0-4, Cmax, and ka, trended down in CC individuals, but not in T allele carriers. Our regression analysis showing that subjects with the highest water-phase digoxin Cmax and AUC0-4 had the largest reductions in these values after juice ingestion suggests an association between degree of intestinal P-gp activity and influence of grapefruit juice on oral digoxin absorption. However, given our small sample, we were unable to establish a clear relationship between MDR1 genotype and the effect of grapefruit juice on digoxin absorption.
Although speculative, interindividual differences in intestinal P-gp activity suggest a possible explanation for the variability in response to grapefruit juice. In individuals with MDR1 genotypes consistent with high P-gp activity and thus low net drug uptake, grapefruit juice would not be expected to affect digoxin absorption significantly since it has minimal effect on intestinal P-gp activity.[20] Conversely, in the setting of low intestinal P-gp activity (high net drug uptake), digoxin absorption may be primarily dependent on uptake by OATP. Since grapefruit juice appears to be a potent inhibitor of OATP transport,[20] the net result is a reduction in digoxin absorption. Thus, the effect of grapefruit juice on OATP is unmasked only in the setting in which P-gp activity is low.
It must be noted that it was not the main purpose of this study to determine genotypic differences in digoxin pharmacokinetics. Our findings are limited by the small number of subjects in each genotypic group: four CC, two CT, and one TT subject(s) at MDR1 nucleotide position 3435. Therefore, we grouped together all three subjects harboring a T allele since the presence of a mutant T allele affects P-gp activity.[43-46] However, since heterozygous carriers of the mutant allele appear to have P-gp substrate pharmacokinetic values and P-gp activity that are intermediate between those of the homozygous groups, our ability to detect genotypic differences in digoxin disposition may have been minimized.[44, 45] Studies with larger numbers of subjects in each C3435T genotype, as well as other linked polymorphisms, are required to determine if an association exists between MDR1 genotype and the effects of grapefruit juice.[44, 46] Of interest, such an association between MDR1 genotype and the effect of clarithromycin on oral digoxin disposition was reported.[46] Polymor-phisms in the genes coding for OATP have been recently identified and could also contribute to interindividual variability in drug disposition.[49, 50]Conclusion
The overall results of this study, using digoxin as a probe, do not support inhibition of intestinal P-gp as an important contributor to grapefruit juice-mediated drug interactions, although significant interindividual variability in the effects of juice was observed. Our preliminary findings suggest the net balance of drug uptake and efflux is a source of variability in grapefruit juice's effect on digoxin absorption. Whether this model is applicable to other P-gp substrate drugs or inhibitors or inducers is unknown and likely depends on the relative contribution of efflux and uptake transporters for a given compound, the net effect of potential interacting substances on drug transporters, as well as drug-metabolizing enzymes. Additional studies are required to characterize more fully the role of MDR1 polymorphisms in drug interactions.
Funding Information
Supported by the ACCP-Aventis Cardiovascular Research Award and by a grant (5MO1RR-00211) from the National Institutes of Health, Washington, D.C.Reprint Address
Address reprint requests to Robert B. Parker, Pharm.D., University of Tennessee, Department of Pharmacy, 26 South Dunlap Street, Memphis, TN 38163.
Section 4 of 4
Pharmacotherapy 23(8):979-987, 2003. © 2003 Pharmacotherapy Publications
This is a part of article Effects of Grapefruit Juice on Intestinal P-glycoprotein Taken from "Discount Allegra Fexofenadine" Information Blog
A family holidaying in Cornwall fear their eight-year-old son may have been permanently scarred by what they thought was a harmless henna tattoo.
A hospital in Suffolk has been criticised for a fundraising plan to offer radiotherapy to family pets.

In This ArticleChapter 8: Me Too!Section 1Section 2Section 3Section 4Section 5Section 6Section 7Section 8Section 9Section 10Section 11ReferencesRelated Links